Moderna, Inc. (MRNA) on Decifer

Why it ranks here

• It is not profitable yet.
• Revenue is expected to grow about 14% a year, profits grew 22% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares.
• Our durability check found pressure on this name, which costs it a few points.

The current read

The evidence on MRNA lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Read the full MRNA research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.